Open Access

Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis

  • Authors:
    • Yu Gao
    • Libo Li
    • Jianbai Yu
    • Zhanwei Zhang
  • View Affiliations

  • Published online on: August 17, 2021     https://doi.org/10.3892/etm.2021.10623
  • Article Number: 1189
  • Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The endoplasmic reticulum stress (ERS) response serves an important role in cerebral ischemia‑reperfusion injury (CIRI). However, to the best of the our knowledge, the effect of rosuvastatin on the ERS response in CIRI has not yet been studied. In the present study, the effect of rosuvastatin on cell damage in CIRI was investigated; furthermore, the effect of rosuvastatin on the ERS response was explored. Firstly, a hypoxia/reoxygenation (H/R)‑induced cell damage model was established in PC12 cells. Cell viability was subsequently detected by a Cell Counting Kit‑8 assay. A lactate dehydrogenase kit was used to detect cytotoxicity. TUNEL assay was then used to measure the extent of cell apoptosis, and western blotting was used to analyze the expression levels of the apoptosis‑associated proteins Bax, Bcl‑2, cleaved caspase‑3 and cleaved caspase‑9. In addition, western blotting was used to detect the expression levels of ERS‑associated proteins, including phosphorylated (p)‑protein kinase R‑like endoplasmic reticulum kinase (PERK), p‑eukaryotic initiation factor 2α and other proteins. Treatment with rosuvastatin led to an increased activity of H/R‑induced PC12 cells and a decrease in their cytotoxicity. Rosuvastatin also led to an inhibition in apoptosis and ERS in H/R‑induced PC12 cells. After administration of the ERS response activator thapsigargin (TG), TG was found to reverse the protective effect of rosuvastatin on injury of H/R‑induced PC12 cells. Taken together, these findings have shown that rosuvastatin is able to protect PC12 cells from H/R‑induced injury via inhibiting ERS‑induced apoptosis, providing a strong theoretical basis for the use of rosuvastatin in the clinical treatment of CIRI.
View Figures
View References

Related Articles

Journal Cover

October-2021
Volume 22 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Gao Y, Li L, Yu J and Zhang Z: Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis. Exp Ther Med 22: 1189, 2021
APA
Gao, Y., Li, L., Yu, J., & Zhang, Z. (2021). Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis. Experimental and Therapeutic Medicine, 22, 1189. https://doi.org/10.3892/etm.2021.10623
MLA
Gao, Y., Li, L., Yu, J., Zhang, Z."Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis". Experimental and Therapeutic Medicine 22.4 (2021): 1189.
Chicago
Gao, Y., Li, L., Yu, J., Zhang, Z."Rosuvastatin protects PC12 cells from hypoxia/reoxygenation‑induced injury by inhibiting endoplasmic reticulum stress‑induced apoptosis". Experimental and Therapeutic Medicine 22, no. 4 (2021): 1189. https://doi.org/10.3892/etm.2021.10623